-
乳腺癌是一种具有多种病理类型和分子分型的异质性疾病,早期诊断和治疗能够提高乳腺癌患者的生存率[1]。乳腺专用γ显像(breast-specific gamma imaging,BSGI)是近年来一种新的核医学分子功能显像方法。与乳腺X线摄影相比,BSGI对乳腺致密型、有瘢痕组织或植入物的患者有更高的诊断灵敏度和特异度[2-3]。研究结果显示,肿瘤与正常组织放射性比值(tumor to normal tissue ratio,TNR)与肿瘤大小和病理学分型等因素相关[4-6]。国内BSGI半定量分析TNR与乳腺癌病理学对比的研究相对较少,且目前TNR的测量方法不同,使得研究结果不一致[5-7],因此值得进一步探讨。本研究中,我们探讨BSGI的TNR与乳腺浸润性导管癌(invasive ductal breast carcinoma,IDC)临床病理学的对比研究价值。
-
84例IDC患者中,BSGI诊断出75例为阳性,灵敏度为89.3%(75/84)(典型病例显像结果见图1~2),9例为阴性。其中右乳病变46例,左乳病变38例,肿瘤大小为0.5~10.0(2.4±1.3) cm。长径<1 cm的患者有15例,肿瘤大小为0.5~0.9(0.7±0.1) cm,其中BSGI诊断出12例为阳性(80%,12/15)。BSGI诊断出20例患者有腋窝淋巴结转移。
-
BSGI诊断结果为阳性与阴性的患者比较:患者年龄的差异无统计学意义(t=8.45,P=0.326)。BSGI显像诊断阳性肿瘤大小为0.5~10.0(2.4±1.8) cm、阴性肿瘤大小为0.7~3.3(1.7±0.9) cm。BSGI诊断阳性与阴性病灶正常组织平均摄取值(每像素计数)的差异无统计学意义(92.3±15.4对94.5±28.6,t=12.54,P=0.475)。
-
BSGI诊断为阳性的75例乳腺癌患者中,单因素分析结果显示,肿瘤大小(t=4.13,P<0.01)、腋窝淋巴结是否转移(χ2=5.04,P=0.005)、不同病理组织学分级(F=11.05,P=0.034)、PR表达(χ2=3.12,P=0.041)和Ki-67指数(χ2=16.20,P=0.008)的TNR差异有统计学意义。多因素分析结果显示,乳腺癌的病理危险因素分别为肿瘤长径≥2 cm(OR=2.186,P=0.004)、腋窝淋巴结转移(OR=1.673,P=0.047)和PR阴性(OR=0.420,P=0.032)(表1)。
参数 例数 TNR ( )$\bar x \pm s $ 单因素分析 多因素分析 t/χ2/F值 P值 OR值 P值 肿瘤大小 4.13 <0.01 2.186 0.004 ≥2 cm 35 4.9±2.3 <2 cm 40 3.2±1.3 腋窝淋巴结转移 5.04 0.005 1.673 0.047 是 19 4.7±1.6 否 56 3.5±1.7 病理亚型 23.14 0.170 − Luminal A型 28 3.3±1.2 Luminal B型 21 4.2±1.8 ERBB2+型 11 4.8±2.7 Basal-like型 15 3.6±2.0 是否为Luminal A型 6.13 0.009 − Luminal A型 31 3.2±1.1 非Luminal A型 44 4.3±1.1 ERBB2+型 2.06 0.301 − 阳性 22 4.3±2.2 阴性 53 3.8±1.3 Basal-like型 3.17 0.462 − 阳性 18 4.3±1.2 阴性 57 3.8±1.6 核分级 8.21 0.126 − 1级 27 2.5±1.1 2级 32 3.7±1.4 3级 16 4.0±1.5 组织学分级 11.05 0.034 − 1级 21 3.1±1.1 2级 25 3.9±1.7 3级 29 4.5±1.8 雌激素受体 2.15 0.072 − 阳性 47 3.6±1.4 阴性 28 4.3±2.2 孕激素受体 3.12 0.041 0.420 0.032 阳性 46 3.6±1.5 阴性 29 4.6±2.3 Ki-67指数 16.20 0.008 − 低(<14%) 40 3.4±1.2 高(≥14%) 35 4.4±1.9 注:表中,ERBB2:酪氨酸激酶受体2;Ki-67:细胞增殖核抗原Ki-67;TNR:肿瘤与正常组织放射性比值;−:单因素分析无统计学差异时,没有进一步行多因素分析 表 1 肿瘤与正常组织放射性比值与乳腺癌临床病理结果的相关性分析(n=75)
Table 1. Correlations between tumor to normal tissue radiation ratio and breast cancer pathology (n=75)
由表1可知,乳腺癌4种病理亚型的TNR之间的差异无统计学意义(F=23.14,P=0.170);而Luminal A型的TNR(3.2±1.1)和非Luminal A型的TNR(4.3±1.1)之间的差异有统计学意义(χ2=6.13,P=0.009)。
Pearson相关性分析结果显示,TNR与肿瘤大小呈弱正相关(r=0.353,P=0.004);与Ki-67指数呈中度正相关(r=0.452,P=0.014);与PR Allred评分呈负相关(r=−0.364,P=0.026)(图3)。
乳腺专用γ显像的肿瘤/正常组织比值与乳腺浸润性导管癌病理学的对比研究
Compared study of tumor uptake target to normal tissue ratio on breast-specific gamma imaging with clinical pathology in invasive ductal breast carcinoma
-
摘要:
目的 探讨乳腺专用γ显像(BSGI)的肿瘤摄取半定量方法与乳腺浸润性导管癌(IDC)临床病理学的对比研究。 方法 回顾性分析2016年4月至2017年8月贵州省人民医院符合纳入标准的84例女性IDC患者,年龄30~76(53.2±13.1)岁。患者术前均行BSGI检查,通过乳腺影像报告和数据系统(BIRADS)对BSGI图像进行视觉评分。根据BSGI的阳性结果,将肿瘤与正常组织放射性比值(TNR)与病理学结果进行比较,阳性与阴性结果的比较采用t检验和χ2检验,多组病理亚型的比较采用方差分析;采用单因素分析、多因素分析和Pearson积差相关性分析明确TNR与组织病理学因素之间的相关性。 结果 84例IDC患者BSGI诊断为阳性75例,灵敏度为89.3%(75/84)。单因素分析结果显示,肿瘤大小(t=4.13,P<0.01)、腋窝淋巴结是否转移(χ2=5.04,P=0.005)、病理组织学分级(F=11.05,P=0.034)、孕激素受体(PR)表达(χ2=3.12,P=0.041)和细胞增殖核抗原Ki-67(简称Ki-67)指数(χ2=16.20,P=0.008)的差异对TNR的影响有统计学意义。多因素分析结果显示,乳腺癌的病理危险因素有肿瘤长径≥2 cm、腋窝淋巴结转移和PR阴性(OR=2.186、1.673、0.420,P=0.004、0.047、0.032)。Pearson相关性分析结果显示,TNR与肿瘤大小的相关性较差(r=0.353,P=0.004);与Ki-67指数呈中度正相关(r=0.452,P=0.014);与PR Allred评分呈负相关(r=−0.364,P=0.026)。 结论 BSGI的高TNR与乳腺癌病理不良因素相关,TNR可作为乳腺癌预后评估的有价值的预测指标。 -
关键词:
- 乳腺肿瘤 /
- 乳腺专用γ显像 /
- 病理学 /
- 肿瘤与正常组织放射性比值
Abstract:Objective To investigate the correlation between tumor uptake target to normal tissue ratio (TNR) obtained from breast-specific gamma imaging (BSGI) and the pathology of breast cancer. Methods A total of 84 female patients aged 30−76(53.2±13.1) years who had visited Guizhou Provincial People's Hospital with a diagnosis of invasive ductal carcinoma and who underwent preoperative BSGI were retrospectively enrolled from April 2016 to August 2017. The BSGI images of these patients were visually scored from 1 to 5 according to a breast imaging reporting and data system (BIRADS). The TNR results obtained from positive BSGI images were compared in terms of breast cancer pathology. T test and chi-square test were used for the comparison of positive and negative results, and analysis of variance was used for the comparison of pathological subtypes among multiple groups.Multiple regression analysis was performed using histologic factors; significant, independent factors were determined by P values less than 0.05 in the univariate analysis. The correlations between TNR and histopathologic factors were analyzed by Pearson’s correlation coefficient. Results Among 84 images, 75 were classified with positive findings (sensitivity 89.3%, 75/84). A higher TNR value was significantly correlated with tumor size (t=4.13, P<0.01), axillary lymph node metastasis (χ2=5.04, P=0.005), histologic grade(HG) (F=11.05, P=0.034), progestrone receptor(PR) status (χ2=3.12, P=0.041), and Ki-67 (χ2=16.20, P=0.008). Multivariate analysis revealed that the pathological risk factors of breast cancer are related to tumor size tumor size≥2 cm, axillary lymph node metastasis, and negative PR status ( OR=2.186, 1.673, 0.420; P=0.004, 0.047, 0.032). Pearson correlation analysis showed that TNR is weakly correlation with tumor size (r=0.353, P=0.004), moderately positively correlated with Ki-67 (r=0.452, P=0.014), a weak negative correlation with the Allred score of PR status (r=−0.364, P=0.026). Conclusion High TNRs in BSGI imaging may be associated with the adverse pathological factors of breast cancer.This parameter may could be a valuable prognostic indicator of breast cancer. -
表 1 肿瘤与正常组织放射性比值与乳腺癌临床病理结果的相关性分析(n=75)
Table 1. Correlations between tumor to normal tissue radiation ratio and breast cancer pathology (n=75)
参数 例数 TNR ( )$\bar x \pm s $ 单因素分析 多因素分析 t/χ2/F值 P值 OR值 P值 肿瘤大小 4.13 <0.01 2.186 0.004 ≥2 cm 35 4.9±2.3 <2 cm 40 3.2±1.3 腋窝淋巴结转移 5.04 0.005 1.673 0.047 是 19 4.7±1.6 否 56 3.5±1.7 病理亚型 23.14 0.170 − Luminal A型 28 3.3±1.2 Luminal B型 21 4.2±1.8 ERBB2+型 11 4.8±2.7 Basal-like型 15 3.6±2.0 是否为Luminal A型 6.13 0.009 − Luminal A型 31 3.2±1.1 非Luminal A型 44 4.3±1.1 ERBB2+型 2.06 0.301 − 阳性 22 4.3±2.2 阴性 53 3.8±1.3 Basal-like型 3.17 0.462 − 阳性 18 4.3±1.2 阴性 57 3.8±1.6 核分级 8.21 0.126 − 1级 27 2.5±1.1 2级 32 3.7±1.4 3级 16 4.0±1.5 组织学分级 11.05 0.034 − 1级 21 3.1±1.1 2级 25 3.9±1.7 3级 29 4.5±1.8 雌激素受体 2.15 0.072 − 阳性 47 3.6±1.4 阴性 28 4.3±2.2 孕激素受体 3.12 0.041 0.420 0.032 阳性 46 3.6±1.5 阴性 29 4.6±2.3 Ki-67指数 16.20 0.008 − 低(<14%) 40 3.4±1.2 高(≥14%) 35 4.4±1.9 注:表中,ERBB2:酪氨酸激酶受体2;Ki-67:细胞增殖核抗原Ki-67;TNR:肿瘤与正常组织放射性比值;−:单因素分析无统计学差异时,没有进一步行多因素分析 -
[1] Ding YN, Chen XG, Zhang QJ, et al. Historical trends in breast cancer among women in China from age-period-cohort modeling of the 1990−2015 breast cancer mortality data[J/OL]. BMC Public Health, 2020, 20(1): 1280[2019-06-08]. https://www.ncbi.nlm.nih.gov/pmc/journals/63. DOI: 10.1186/s12889-020-09375-0. [2] Sun Y, Wei W, Yang HW, et al. Clinical usefulness of breast-specific gamma imaging as an adjunct modality to mammography for diagnosis of breast cancer: a systemic review and meta-analysis[J]. Eur J Nucl Med Mol Imaging, 2013, 40(3): 450−463. DOI: 10.1007/s00259-012-2279-5. [3] Huppe AI, Mehta AK, Brem RF. Molecular breast imaging: A comprehensive review[J]. Semin Ultrasound CT MR, 2018, 39(1): 60−69. DOI: 10.1053/j.sult.2017.10.001. [4] Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies-improving the management of early breast cancer: St Gallen international expert consensus on the primary therapy of early breast cancer 2015[J]. Ann Oncol, 2015, 26(8): 1533−1546. DOI: 10.1093/annonc/mdv221. [5] Meissnitzer T, Meissnitzer MW, Seymer A, et al. Relative uptake factor of invasive ductal breast cancer in breast-specific gamma imaging as a surrogate parameter for sub-typing[J]. Anticancer Res, 2015, 35(10): 5671−5677. [6] Tan H, Zhang HW, Yang WG, et al. Breast-specific gamma imaging with Tc-99m-sestamibi in the diagnosis of breast cancer and its semiquantitative index correlation with tumor biologic markers, subtypes, and clinicopathologic characteristics[J]. Nucl Med Commun, 2016, 37(8): 792−799. DOI: 10.1097/MNM.0000000000000518. [7] Yoon HJ, Kim Y, Chang KT, et al. Prognostic value of semi-quantitative tumor uptake on Tc-99m sestamibi breast-specific gamma imaging in invasive ductal breast cancer[J]. Ann Nucl Med, 2015, 29(7): 553−560. DOI: 10.1007/s12149-015-0977-3. [8] Goldsmith SJ, Parsons W, Guiberteau MJ, et al. SNM practice guideline for breast scintigraphy with breast-specific gamma-cameras 1.0[J]. J Nucl Med Technol, 2010, 38(4): 219−224. DOI: 10.2967/jnmt.110.082271. [9] Lee SJ, Choi YY, Kim C, et al. Correlations between tumor to background ratio on breast-specific gamma imaging and prognostic factors in breast cancer[J]. J Korean Med Sci, 2017, 32(6): 1031−1037. DOI: 10.3346/jkms.2017.32.6.1031. [10] Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[J]. J Clin Oncol, 2010, 28(16): 2784−2795. DOI: 10.1200/JCO.2009.25.6529. [11] Inda MA, Blok EJ, Kuppen PJK, et al. Estrogen receptor pathway activity score to predict clinical response or resistance to neoadjuvant endocrine therapy in primary breast cancer[J]. Mol Cancer Ther, 2020, 19(2): 680−689. DOI: 10.1158/1535-7163.MCT-19-0318. [12] Gradishar WJ, Anderson BO, Balassanian R, et al. NCCN guidelines insights: breast cancer, version 1.2017[J]. J Natl Compr Canc Netw, 2017, 15(4): 433−451. DOI: 10.6004/jnccn.2017.0044. [13] Narayanan D, Berg WA. Dedicated breast gamma camera imaging and breast PET: current status and future directions[J]. PET Clin, 2018, 13(3): 363−381. DOI: 10.1016/j.cpet.2018.02.008. [14] Sanli Y, Kuyumcu S, Ozkan ZG, et al. Increased FDG uptake in breast cancer is associated with prognostic factors[J]. Ann Nucl Med, 2012, 26(4): 345−350. DOI: 10.1007/s12149-012-0579-2. [15] Kim J, Yoo SW, Kang SR, et al. Prognostic significance of metabolic tumor volume measured by 18F-FDG PET/CT in operable primary breast cancer[J]. Nucl Med Mol Imaging, 2012, 46(4): 278−285. DOI: 10.1007/s13139-012-0161-9. [16] Papantoniou V, Christodoulidou J, Papadaki E, et al. Uptake and washout of 99mTcV-dimercaptosuccinic acid and 99mTc-sestamibi in the assessment of histological type and grade in breast cancer[J]. Nucl Med Commun, 2002, 23(5): 461−467. DOI: 10.1097/00006231-200205000-00006. [17] Papantoniou VJ, Souvatzoglou MA, Valotassiou VJ, et al. Relationship of cell proliferation (Ki-67) to 99mTc-(V)DMSA uptake in breast cancer[J]. Breast Cancer Res, 2004, 6(2): R56−R62. DOI: 10.1186/bcr751. [18] Kim S, Plemmons J, Hoang K, et al. Breast-Specific gamma imaging versus MRI: comparing the diagnostic performance in assessing treatment response after neoadjuvant chemotherapy in patients with breast cancer[J]. AJR Am J Roentgenol, 2019, 212(3): 696−705. DOI: 10.2214/AJR.17.18930. [19] Cwikla JB, Buscombe JR, Kolasinska AD, et al. Correlation between uptake of Tc-99m sestaMIBI and prognostic factors of breast cancer[J]. Anticancer Res, 1999, 19(3B): 2299−2304. [20] Tadwalkar RV, Rapelyea JA, Torrente J, et al. Breast-specific gamma imaging as an adjunct modality for the diagnosis of invasive breast cancer with correlation to tumour size and grade[J]. Br J Radiol, 2012, 85(1014): e212−e216. DOI: 10.1259/bjr/34392802. [21] Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2015, 26(Suppl 5): Sv8−30. DOI: 10.1093/annonc/mdv298.